BioLineRx Ltd Cash Flow-to-Debt Ratio
BioLineRx Ltd cash flow-to-debt ratio. BioLineRx Ltd (BLRX) has a Cash Flow-to-Debt Ratio of -0.19x as of June 2026, meaning its operating cash flow of $-3.26 Million could theoretically repay 0% of its total liabilities ($16.86 Million) in one year. Check earnings quality score of BioLineRx Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BioLineRx Ltd (2008–2025)
Cash flow-to-debt ratio of BioLineRx Ltd from 2008 to 2025. Historical debt coverage capacity for BioLineRx Ltd across 18 annual periods. Check BLRX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BioLineRx Ltd Cash Flow-to-Debt Ratio by Year (2008–2025)
BioLineRx Ltd cash flow-to-debt ratio by year from 2008 to 2025. Year-by-year debt coverage analysis for BioLineRx Ltd. For the full cash flow conversion analysis, see BioLineRx Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.46x | $-8.14 Million | $17.56 Million | ▲ +73.1% |
| 2024 | -1.72x | $-43.87 Million | $25.45 Million | ▼ -286.7% |
| 2023 | -0.45x | $-22.61 Million | $50.70 Million | ▲ +56.6% |
| 2022 | -1.03x | $-26.24 Million | $25.54 Million | ▲ +42.0% |
| 2021 | -1.77x | $-23.57 Million | $13.30 Million | ▼ -92.9% |
| 2020 | -0.92x | $-23.21 Million | $25.26 Million | ▲ +18.2% |
| 2019 | -1.12x | $-22.67 Million | $20.19 Million | ▲ +30.8% |
| 2018 | -1.62x | $-24.19 Million | $14.91 Million | ▲ +36.2% |
| 2017 | -2.54x | $-20.55 Million | $8.08 Million | ▲ +31.5% |
| 2016 | -3.71x | $-14.51 Million | $3.91 Million | ▲ +3.3% |
| 2015 | -3.84x | $-14.17 Million | $3.69 Million | ▼ -16.6% |
| 2014 | -3.29x | $-14.48 Million | $4.40 Million | ▼ -34.4% |
| 2013 | -2.45x | $-20.23 Million | $8.27 Million | ▼ -13.6% |
| 2012 | -2.15x | $-20.11 Million | $9.34 Million | ▼ -30.7% |
| 2011 | -1.65x | $-11.22 Million | $6.81 Million | ▼ -192.0% |
| 2010 | 1.79x | $11.46 Million | $6.40 Million | ▲ +190.7% |
| 2009 | -1.98x | $-21.51 Million | $10.88 Million | ▲ +30.1% |
| 2008 | -2.83x | $-27.96 Million | $9.89 Million | — |